Latest Conference Articles

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine failed to significantly improve the primary endpoint of overall survival (OS) in a phase II study for patients with metastatic urothelial cancer.

The investigational anti-PD-L1 antibody avelumab showed antitumor activity within acceptable safety profile parameters in a recent phase Ib trial for metastatic urothelial cancer refractory to standard therapy.

Hypofractionated radiotherapy and standard radiation therapy demonstrated similar toxicities and neither prevented PSA increases or disease recurrences for men with intermediate-risk prostate cancer better than the other, according to data from the phase III randomized CHHiP trial reported at the 2016 GU Cancers Symposium.

Second-line treatment with atezolizumab (MPDL3280A) resulted in a median overall survival (OS) of 11.4 months in patients with locally advanced or metastatic urothelial carcinoma (mUC) and who showcased high PD-L1 levels.

A post hoc analysis of the phase III COU-AA-302 clinical trial suggests docetaxel can produce antitumor activity as the first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naive, metastatic castration-resistant prostate cancer.

Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.

Agarwal says patients whose penile cancer does not spread to their lymph nodes have a 95% chance of survival over the course of 5 years, while survival for those whose cancer spreads to their lymph nodes is significantly less.

Emberton says that in treatment of most solid tumor cancers, oncologists have moved from treating the whole organ to specifically targeting the tumor.

Aspirin, normally associated with heart health, may not extend to the reduction of risk in prostate cancer, according to the results of an observational study.

Resistance to androgen receptor therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) has historically posed a challenge to clinicians. Now, a new blood test that analyzes circulating tumor cells (CTCs) could help overcoming these hurdles.

In a comparison study, cabozantinib significantly boosted progression-free survival (PFS) against everolimus in patients with renal cell carcinoma (RCC) regardless of metastases degree, type, number of prior treatments, or patient risk status.

Saad Usmani, MD, discusses newly approved treatments, as well as these combination therapies currently in clinical trials.

With numerous newly approved drugs for patients with early-stage multiple myeloma reaching the clinics, understanding what drugs, combinations, and sequences to use has become an important area of research. Several recent studies have demonstrated increased efficacy with nominally increased adverse events in these triplet arms.

Neal Young, MD, discusses the advancement of treatment for aplastic anemia. Young said aplastic anemia used to kill almost all patients diagnosed with the disease within a year.

Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).

Amy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).

Carboplatin combined with neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.

A follow-up benefits analysis of adding denosumab to aromatase inhibitor (AI) therapy shows the agent not only helps prevent fractures, it also reduces risk of recurrence and death in postmenopausal women with HR-positive breast cancer.

A combination of venetoclax and obinutuzumab, followed by additional cycles of venetoclax, has shown tolerability in elderly patients with previously untreated chronic lymphocytic leukemia with comorbidities, data from the CLL14 trial (BO25323) shows.

A combination of capecitabine and adjuvant therapy dropped the risk of recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer post-neoadjuvant chemotherapy and surgery, according to phase III data.

Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.

The PD-1 inhibitor pembrolizumab in combination with an established multiple myeloma regimen showed responses in 76% of a cohort of 17 patients with relapsed/refractory disease in data one of several clinical trials presented at the 2015 ASH Annual Meeting.

Blinatumomab (Blincyto) as a single agent showed high complete remission (CR), or CR with partial hematological recovery, in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.

David Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.

Ibrutinib (Imbruvica) saw over 80% response in patients with treatment-refractory Waldenstrom

Two CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies showed complete response (CR) rates from 90% to 100% in patients with high-risk acute lymphoblastic leukemia (ALL), according to data from two studies presented during the 2015 ASH Annual Meeting.

Updated data shows chimeric antigen receptor (CAR)-modified T-cell therapies continue to remain effective for patients with non-Hodgkin lymphoma (NHL), according to findings presented at the 2015 ASH Annual Meeting.

Novel BCL-2 inhibitor venetoclax showed a near 80% overall response rate (ORR) in patients with chronic lymphocytic leukemia harboring a chromosome 17p deletion.

Ibrutinib reduced risk of death by 84% against chlorambucil in treatment-naive elderly patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma.